Desmopressin in Cardiac Surgery

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients undergoing cardiac surgery could develop excessive perioperative bleeding requiring transfusions of blood products.

Desmopressin (DDAVP), already used for patients with von Willebrand syndrome, could reduce bleeding and transfusion requirements in these patients when administered ev (0.3 mg/kg) in 20-30 minutes postoperatively.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Università Vita-Salute San Raffaele
• Treatments: Deamino Arginine Vasopressin

Criteria

Inclusion Criteria:

• undergoing cardiac surgery

• excessive bleeding

Exclusion Criteria:

• age<18 y

• not signing written consent